SeaStar Medical shares are trading higher after the company announced it was granted Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device for Cardiorenal Syndrome.
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical has been granted Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device for Cardiorenal Syndrome. This has led to a rise in the company's stock.
September 29, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical's stock is trading higher after the FDA granted Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome.
The FDA's Breakthrough Device Designation is a significant regulatory milestone that can lead to increased investor confidence and a rise in stock price. Given that SeaStar Medical's device is aimed at treating Cardiorenal Syndrome, a condition with high unmet medical need, this news is highly relevant and important for ICU investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100